Xvivo Perfusion Management
Management criteria checks 3/4
Xvivo Perfusion's CEO is Christoffer Rosenblad, appointed in Jan 2022, has a tenure of 3.33 years. total yearly compensation is SEK7.39M, comprised of 52.5% salary and 47.5% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $1.61M. The average tenure of the management team and the board of directors is 3.9 years and 4.6 years respectively.
Key information
Christoffer Rosenblad
Chief executive officer
SEK 7.4m
Total compensation
| CEO salary percentage | 52.5% |
| CEO tenure | 3.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.9yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | SEK 137m |
| Dec 31 2024 | SEK 7m | SEK 4m | SEK 172m |
| Sep 30 2024 | n/a | n/a | SEK 204m |
| Jun 30 2024 | n/a | n/a | SEK 121m |
| Mar 31 2024 | n/a | n/a | SEK 100m |
| Dec 31 2023 | SEK 5m | SEK 3m | SEK 92m |
| Sep 30 2023 | n/a | n/a | SEK 24m |
| Jun 30 2023 | n/a | n/a | SEK 27m |
| Mar 31 2023 | n/a | n/a | SEK 28m |
| Dec 31 2022 | SEK 782k | n/a | SEK 18m |
Compensation vs Market: Christoffer's total compensation ($USD764.91K) is below average for companies of similar size in the US market ($USD4.04M).
Compensation vs Earnings: Christoffer's compensation has increased by more than 20% in the past year.
CEO
Christoffer Rosenblad (49 yo)
3.3yrs
Tenure
SEK 7,386,000
Compensation
Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 3.3yrs | SEK 7.39m | 0.16% $ 1.6m | |
| Chief Financial Officer | 4.5yrs | no data | 0.0085% $ 83.2k | |
| COO & Deputy CEO | 2.4yrs | no data | 0.011% $ 109.3k | |
| Senior Vice President of Human Resources | 2.3yrs | no data | no data | |
| Senior Advisor | 4.9yrs | SEK 1.62m | no data | |
| Chief Medical Officer | 4.7yrs | no data | 0.011% $ 106.5k | |
| Senior Vice President of Commercial Europe & RoW | 4.7yrs | no data | 0.012% $ 115.8k | |
| Senior Vice President of Clinical & Regulatory Affairs North America | no data | no data | no data | |
| Senior Vice President of North America | 1.3yrs | no data | no data |
3.9yrs
Average Tenure
54yo
Average Age
Experienced Management: XVIP.Y's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 12.3yrs | SEK 480.00k | 0.015% $ 146.8k | |
| Independent Director | 4.6yrs | no data | 0.0076% $ 75.0k | |
| Independent Director | 2.1yrs | no data | 0.18% $ 1.8m | |
| Independent Director | 9yrs | SEK 130.00k | 0.0034% $ 33.6k | |
| Independent Director | 4.6yrs | no data | 0.0041% $ 40.6k | |
| Independent Director | 3.1yrs | no data | no data | |
| Director | less than a year | no data | no data |
4.6yrs
Average Tenure
63.5yo
Average Age
Experienced Board: XVIP.Y's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 05:23 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| Maria Vara Fernández | Bryan Garnier & Co |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |